Analyst Price Targets — AVLN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 13, 2026 11:34 am | — | Morgan Stanley | $57.00 | $37.38 | TheFly | Avalyn Pharma price target raised to $57 from $53 at Morgan Stanley |
| May 26, 2026 12:41 pm | Gavin Clark-Gartner | Evercore ISI | $51.00 | $28.41 | TheFly | Avalyn Pharma initiated with an Outperform at Evercore ISI |
| May 26, 2026 9:15 am | — | Morgan Stanley | $53.00 | $28.84 | TheFly | Avalyn Pharma initiated with an Overweight at Morgan Stanley |
| May 25, 2026 11:01 am | — | Jefferies | $52.00 | $28.84 | TheFly | Avalyn Pharma initiated with a Buy at Jefferies |
| May 25, 2026 10:42 am | — | Guggenheim | $80.00 | $28.84 | TheFly | Avalyn Pharma initiated with a Buy at Guggenheim |
Latest News for AVLN
Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs
Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Society (ERS) Congress, including data modeling AP01 lung tissue distribution Ended the second quarter of 2026 with $413.5 million in cash, cash equivalents and marketable securities; cash runway projected into 2029 BOSTON,…
Company expects to report topline 12-month clinical results in the second half of 2027 Company expects to report topline 12-month clinical results in the second half of 2027
Avalyn Pharma NASDAQ: AVLN executives outlined the company's inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position its candidates as potential backbone therapies for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability profile
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for AVLN.
Senate Trading
No Senate trades found for AVLN.
U.S. House Trading
No House trades found for AVLN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.